Status:
UNKNOWN
Ranibizumab Versus Aflibercept for CRVO in Young Patients.
Lead Sponsor:
South Valley University
Conditions:
Non-Ischemic Central Retinal Vein Occlusion With Macular Edema
Eligibility:
All Genders
Up to 50 years
Phase:
PHASE4
Brief Summary
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger t...
Detailed Description
This is a prospective randomized interventional study, Forty eyes of forty patients younger than 50 years with macular edema due to non-ischemic CRVO were enrolled in the study. Patients will be rand...
Eligibility Criteria
Inclusion
- patients younger than 50 years with macular edema due to non-ischemic CRVO
Exclusion
- Other conditions that might affect the macula as
- diabetic retinopathy, intraocular inflammation, age related macular degeneration, patients with solar or radiation retinopathy,
- patients with ischemic type CRVO and patients who had recent intraocular surgery.
- patients who had previous intravitreal injections, ophthalmic laser surgeries.
- patients with dense cataracts whom fundus was difficult to scan.
- Patients who were lost to follow up visits were also excluded
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05282420
Start Date
February 1 2021
End Date
May 31 2022
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed Ali Ahmed Amer
Qina, Qena Governorate, Egypt, 83523